We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.
- Authors
Carella, Angelo M.; Santini, Gino; Martinengo, Marina; Giordano, Domenico; Nati, Sandro; Congiu, Angela; Cerri, Raffaella; Risso, Marco; Damasio, Eugenio; Rossi, Edoardo; Vimercati, Renato; Pacciarini, Maria A.; Marmont, Alberto M.; Carella, A M; Santini, G; Martinengo, M; Giordano, D; Nati, S; Congiu, A; Cerri, R
- Abstract
Twenty-five adults with previously treated acute leukemia were treated with 4-demethoxydaunorubicin (Idarubicin) with a daily dose of 8 mg/m2 for 3 days intravenously. Complete remission was achieved in 3 of 18 patients with acute nonlymphoblastic leukemia (ANLL) and 2 of 6 with lymphoblastic leukemia. Complete remissions were observed in two of eight ANLL patients refractory to cytarabine, anthracycline, and m-Amsa (amsacrine), indicating a lack of cross-resistance between these drugs and Idarubicin. The median duration of remission was 8 weeks. The main major toxicity of Idarubicin therapy, severe myelosuppression, cannot be considered a toxic effect because it was desired in this case list. Our preliminary results indicate that Idarubicin has significant activity against refractory adult acute leukemia.
- Subjects
DAUNOMYCIN; DRUG resistance; CLINICAL drug trials; LEUKEMIA; LYMPHOCYTIC leukemia; PILOT projects; ACUTE diseases; IDARUBICIN
- Publication
Cancer (0008543X), 1985, Vol 55, Issue 7, p1452
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19850401)55:7<1452::AID-CNCR2820550705>3.0.CO;2-D